Norges Bank’s Minerva Neurosciences NERV Stock Holding History

Norges Bank’s Portfolio NERV Stock Details NERV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-8,929	Closed	-$839K	–	2166
2016 Q4	$839K	Buy	+8,929	New	+$911K	﹤0.01%	2077

Other funds holding NERV

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Norges Bank's NERV Position: Q1 2017 in Review

Norges Bank sold out of Minerva Neurosciences (NERV) in Q1 2017, closing a stake of 8,929 shares — an estimated $839K sold.

Norges Bank first reported a position in NERV in Q4 2016 and held it in 1 quarter. The position peaked at $839K in Q4 2016. 71 funds tracked by Wall St. Rank hold NERV as of Q1 2017.

Norges Bank reported no remaining Minerva Neurosciences position as of Q1 2017 after selling out during the quarter.
Norges Bank sold 8,929 Minerva Neurosciences shares in Q1 2017, an estimated $839K.
Norges Bank first reported a position in Minerva Neurosciences in Q4 2016 and held it in 1 quarter.
Norges Bank's Minerva Neurosciences position peaked at $839K in Q4 2016.
71 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q1 2017.

Based on Norges Bank's 13F filing for Q1 2017, filed 10 May 2017.